Print

Active Biotech in brief

Active Biotech is a company with focus on research and development of pharmaceutical products within medical areas where the immune defense is of significant importance. The research portfolio essentially contains projects for development of pharmaceuticals for neurodegenerative/inflammatory diseases and cancer.

Active Biotech currently has two projects in late clinical Phase, laquinimod and tasquinimod, both of which are out-licensed.

The laquinimod project is focused on the treatment of neurodegenerative diseases. The diseases in which clinical development is ongoing are RRMS, PPMS and Huntington’s disease. The project has undergone, and is currently undergoing, a highly comprehensive clinical development program.

The tasquinimod project has been developed for the treatment of cancer, primarily metastatic Castrate Resistant Prostate Cancer (mCRPC).

In addition, Active Biotech is pursuing a pre-clinical project, ISI. This project has, based on pre-clinical studies, potential treatment applications in both degenerative diseases and cancer.